Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial

Saskia F A Duijts, Hester S A Oldenburg, Marc van Beurden, Neil K Aaronson, Saskia F A Duijts, Hester S A Oldenburg, Marc van Beurden, Neil K Aaronson

Abstract

Background: Premature menopause is a major concern of younger women undergoing adjuvant therapy for breast cancer. Hormone replacement therapy is contraindicated in women with a history of breast cancer. Non-hormonal medications show a range of bothersome side-effects. There is growing evidence that cognitive behavioral therapy (CBT) and physical exercise can have a positive impact on symptoms in naturally occurring menopause. The objective of this study is to investigate the efficacy of these interventions among women with breast cancer experiencing treatment-induced menopause.

Methods/design: In a randomized, controlled, multicenter trial, we are evaluating the effectiveness of CBT/relaxation, of physical exercise and of these two program elements combined, in reducing menopausal symptoms, improving sexual functioning, reducing emotional distress, and in improving the health-related quality of life of younger breast cancer patients who experience treatment-induced menopause. 325 breast cancer patients (aged < 50) are being recruited from hospitals in the Amsterdam region, and randomly allocated to one of the three treatment groups or a 'waiting list' control group. Self-administered questionnaires are completed by the patients at baseline, and at 12 weeks (T1) and 6 months (T2) post-study entry. Upon completion of the study, women assigned to the control group will be given the choice of undergoing either the CBT or physical exercise program.

Discussion: Cognitive behavioral therapy and physical exercise are potentially useful treatments among women with breast cancer undergoing treatment-induced, premature menopause. For these patients, hormonal and non-hormonal therapies are contraindicated or have a range of bothersome side-effects. Hence, research into these interventions is needed, before dissemination and implementation in the current health care system can take place.

Trial registration: ClinicalTrials.gov NCT00582244.

Figures

Figure 1
Figure 1
Study flow diagram.

References

    1. Visser O, Siesling S, van Dijk J. Incidence of cancer in the Netherlands 1999/2000: Eleventh report of the Netherlands Cancer Registry. Utrecht: Association of Integral Cancer Centers; 2003.
    1. American Cancer Society – Cancer Facts Figures – 2000. Atlanta, GA: American Cancer Society; 2003.
    1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.
    1. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344:1997–2008. doi: 10.1056/NEJM200106283442607.
    1. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.
    1. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology. 2004;13:295–308.
    1. Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003;45:29–38. doi: 10.1016/S0378-5122(03)00087-2.
    1. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995;13:2737–44.
    1. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998;16:501–14.
    1. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;509;23:501. doi: 10.1016/S0885-3924(02)00395-0.
    1. Angelopoulos N, Barbounis V, Livadas S, Kaltsas D, Tolis G. Effects of estrogen deprivation due to breast cancer treatment. Endocr Relat Cancer. 2004;11:523–35. doi: 10.1677/erc.1.00783.
    1. Rostom AY. The management of menopausal sequelae in patients with breast cancer. Clin Oncol (R Coll Radiol) 2001;13:174–80.
    1. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs. 1996;19:308–19. doi: 10.1097/00002820-199608000-00007.
    1. Bloom JR, Stewart SL, Chang S, Banks PJ. Then and now: quality of life of young breast cancer survivors. Psychooncology. 2004;13:147–60. doi: 10.1002/pon.794.
    1. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum. 1999;26:1311–7.
    1. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer. 1998;82:1682–91. doi: 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>;2-0.
    1. Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman I, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology. 2004;13:769–78. doi: 10.1002/pon.793.
    1. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77:1207–18. doi: 10.4065/77.11.1207.
    1. Gannon L, Hansel S, Goodwin J. Correlates of menopausal hot flashes. J Behav Med. 1987;10:277–85. doi: 10.1007/BF00846541.
    1. Swartzman LC, Edelberg R, Kemmann E. Impact of stress on objectively recorded menopausal hot flushes and on flush report bias. Health Psychol. 1990;9:529–45. doi: 10.1037/0278-6133.9.5.529.
    1. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review) 2004.
    1. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–5. doi: 10.1016/S0140-6736(04)15493-7.
    1. Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother. 2004;38:1482–99. doi: 10.1345/aph.1D610.
    1. Caley CF, Weber SS. Paroxetine: a selective serotonin reuptake inhibiting antidepressant. Ann Pharmacother. 1993;27:1212–22.
    1. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355:911–8. doi: 10.1016/S0140-6736(99)11381-3.
    1. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol. 1982;60:583–6.
    1. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol. 1987;156:561–5.
    1. Hunter MS. Cognitive behavioural interventions for premenstrual and menopausal problems. J Reprod Infant Psychol. 2003:183–93. doi: 10.1080/0264683031000155006.
    1. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol. 1996;17:202–7. doi: 10.3109/01674829609025684.
    1. Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas. 2004;48:97–105. doi: 10.1016/S0378-5122(03)00187-7.
    1. Hunter MS, Liao KLM. Evaluation of a four session cognitive behavioural intervention for menopausal hot flushes. Br J Health Psychol. 1996;1:113–25.
    1. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992;167:436–9.
    1. Stevenson DW, Delprato DJ. Multiple component self-control program for menopausal hot flashes. J Behav Ther Exp Psychiatry. 1983;14:137–40. doi: 10.1016/0005-7916(83)90031-9.
    1. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000;92:1054–64. doi: 10.1093/jnci/92.13.1054.
    1. Fenlon D. Relaxation therapy as an intervention for hot flushes in women with breast cancer. Eur J Oncol Nurs. 1999;3:223–31. doi: 10.1016/S1462-3889(99)81335-0.
    1. Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas. 1998;29:139–46. doi: 10.1016/S0378-5122(98)00004-8.
    1. Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh C, Nerbrand C. Menopause-related symptoms: What are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study) Am J Obstet Gynecol. 2003;189:1646–53. doi: 10.1016/S0002-9378(03)00872-X.
    1. Ueda M. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women. J Physiol Anthropol Appl Human Sci. 2004;23:143–8. doi: 10.2114/jpa.23.143.
    1. Aiello EJ, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Bowen D, et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause. 2004;11:382–8. doi: 10.1097/01.GME.0000113932.56832.27.
    1. Rice VM. Effect of moderate-intensity exercise in alleviating menopausal symptoms. Menopause. 2004;11:372–4. doi: 10.1097/01.GME.0000134181.75710.52.
    1. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189–99. doi: 10.1023/A:1006263818115.
    1. Cohen J. Statistical power analysis for the behavioral sciences. Hilsdale, NJ: Lawrence Earlbaum Associates; 1988.
    1. Madalinska JB, Hollenstein J, Bleiker EMA, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. The quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;34:589–99.
    1. Hunter MS, Liao KLM. A psychological analysis of menopausal hot flushes. Br J Clin Psychol. 1995;34:589–99.
    1. Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. Then and now: quality of life of young breast cancer survivors. Am J Obstet Gynecol. 2004;191:73–82. doi: 10.1016/j.ajog.2003.12.027.
    1. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women's sexual functioning. Qual Life Res. 1996;5:81–90. doi: 10.1007/BF00435972.
    1. Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol. 2001;19:1885–92.
    1. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002;94:39–49.
    1. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–93. doi: 10.1200/JCO.2003.04.196.
    1. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756–68.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. de Bock GH, Bonnema J, Zwaan RE, Velde CJ van de, Kievit J, Stiggelbout AM. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004;90:1144–50. doi: 10.1038/sj.bjc.6601655.
    1. Turner J, Kelly B, Swanson C, Allison R, Wetzig N. Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology. 2005;14:396–407. doi: 10.1002/pon.856.
    1. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27:363–70. doi: 10.1017/S0033291796004382.
    1. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83. doi: 10.1097/00005650-199206000-00002.
    1. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–68. doi: 10.1016/S0895-4356(98)00097-3.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner